^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Integrin beta-6-targeted antibody-drug conjugate

    Related drugs:
    1m
    JSKN022 in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=225, Recruiting, Jiangsu Alphamab Biopharmaceuticals Co., Ltd
    New P1 trial
    1m
    A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=6, Completed, Seagen, a wholly owned subsidiary of Pfizer | Active, not recruiting --> Completed
    Trial completion
    |
    sigvotatug vedotin (PF-08046047)
    1m
    Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design. (PubMed, Future Oncol)
    Approximately 714 patients will be randomized 1:1. The dual primary endpoints are progression-free survival as assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumors v1.1 and overall survival; secondary endpoints include additional efficacy, safety and tolerability, pharmacokinetics, and immunogenicity endpoints.Clinical trial registration: NCT06758401 (https://clinicaltrials.gov/study/NCT06758401).
    P3 data • Journal • Tumor proportion score • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • sigvotatug vedotin (PF-08046047)
    3ms
    A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer (clinicaltrials.gov)
    P1, N=294, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    sasanlimab (PF-06801591)
    3ms
    A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of JSKN022 in Subjects with Advanced Malignant Solid Tumors (ChiCTR2500110741)
    P1, N=225, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P1 trial
    4ms
    A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=310, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    4ms
    A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Aug 2025 --> Nov 2025 | Trial primary completion date: Aug 2025 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    sigvotatug vedotin (PF-08046047)
    5ms
    Be6A Lung-01: A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=703, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | N=470 --> 703
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    docetaxel • sigvotatug vedotin (PF-08046047)
    6ms
    A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=310, Not yet recruiting, Pfizer
    New P1 trial
    6ms
    SGNB6A-001: A Study of Sigvotatug Vedotin in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=1006, Recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: May 2028 --> Mar 2029 | Trial primary completion date: Aug 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • sigvotatug vedotin (PF-08046047)
    6ms
    Be6A Lung-01: A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=470, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    docetaxel • sigvotatug vedotin (PF-08046047)
    8ms
    BE6A LUNG-02: This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. (clinicaltrials.gov)
    P3, N=714, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • sigvotatug vedotin (PF-08046047)